Captain T Cell Closes Financing Round to Advance its Proprietary, Next-Generation TCR-T ...

Captain T Cell Closes Financing Round to Advance its Proprietary, Next-Generation TCR-T ...

Available funding totaling EUR 20 million dedicated to developing novel solid tumor treatments addressing a high unmet medical needSpringboard Health Angels, Pluton Asset Holding AG, Sintra Limited, and Technologiegründerfonds Sachsen joined as new investorsExisting investors i&i Biotech Fund I SCSp,…

Engineering the Future of Medicine: How Next-generation Cell Therapies Are Redefining Precision Healthcare

Open the article to view the coverage from frost.com

Millions Flow Into Captain T Cell as Berlin’s Cell Therapy Scene Defies the Gloom - European Biotechnology Magazine

The company Captain T Cell, spin-out from Max-Delbrück center in Berlin, now has a total of €20 million in funding and grants to push forward its novel cell therapies for solid tumours. New backers include Springboard Health Angels, Pluton Asset Holding, Sintra Limited and the Technologiegründerfonds Sachsen, joining the existing investor base. The new tennant in Bayer´s Co.Lab in Berlin City does starts with positive vibes. The post Millions Fl…